Janux Therapeutics, Inc. JANX
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- +26.59%
- 1 year
- -38.72%
- Open
- 17.93
- Prev close
- 17.83
- Mkt cap
- 1.07B
- Vol
- 540.04K
- Avg vol
- 826.55K
- EPS
- -1.64
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 17.13
- High
- 18.17
- Forward P/E
- -6.66
- Beta
- 2.39
- Short ratio
- 5.72
- Inst. own
- 101.14%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 17.59
- 200-d avg
- 15.31
- 1y target
- 33.81
News
2 weeks ago defenseworld.net
Janux Therapeutics (NASDAQ:JANX) and Zai Lab (NASDAQ:ZLAB) Head-To-Head Survey
Zai Lab (NASDAQ: ZLAB - Get Free Report) and Janux Therapeutics (NASDAQ: JANX - Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies…
3 weeks ago defenseworld.net
Head-To-Head Review: Janux Therapeutics (NASDAQ:JANX) and Roivant Sciences (NASDAQ:ROIV)
Janux Therapeutics (NASDAQ: JANX - Get Free Report) and Roivant Sciences (NASDAQ: ROIV - Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two…
1 month ago zacks.com
4 Prostate Cancer Drug Stocks to Watch During Awareness Month
Pfizer, Novartis, Janux Therapeutics and Candel Therapeutics offer varied prostate-cancer exposure, with established drugs and clinical or regulatory catalysts.
-
1 month ago benzinga.com
Janux Therapeutics Doses First Patient In The Phase 1 Clinical Trial For JANX013, Its PSMA-Targeted Tumor-Activated CD28 Co-Stimulatory Bispecific, In Patients With Metastatic Castration-Resistant Prostate Cancer
The program is initially being developed in combination with JANX007, with the goal of further enhancing the durability of anti-tumor immune responses through tumor-restricted CD28 co-stimulation.…
1 month ago businesswire.com
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX), a clinical-stage biotechnology company developing tumor-activated immunotherapies, today announced that the first patient has been…
2 months ago benzinga.com
This Darden Analyst Turns Bullish; Here Are Top 4 Upgrades For Monday
Top Wall Street analysts changed their outlook on top names. See analyst ratings page for full list. DRI, JANX, and more mentioned.
-
2 months ago benzinga.com
Wolfe Research Upgrades Janux Therapeutics to Outperform, Announces $23 Price Target
Wolfe Research analyst Kalpit Patel upgrades Janux Therapeutics (NASDAQ:JANX) from Peer Perform to Outperform and announces $23 price target.
2 months ago 247wallst.com
Here Are Monday’s Top Wall Street Analyst Research Calls: AstraZeneca, Celestica, Chipotle Mexican Grill, Domino’s Pizza, Fortune Brands, Golar LNG, Jersey Mike’s Subs, Roku, and More
Wall Street analysts reshuffled the deck on Monday with a wave of upgrades, downgrades, and fresh initiations spanning pharma giants, fast-casual chains, and streaming players. Find out which names…
2 months ago zacks.com
JANX Shares Gain 19.1% in 3 Months: Here's What You Need to Know
Janux stock climbs 19.1% in three months as pipeline progress, upcoming catalysts and a strong cash position boost investor confidence.
-
2 months ago benzinga.com
Guggenheim Maintains Buy on Janux Therapeutics, Lowers Price Target to $55
Guggenheim analyst Brad Canino maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and lowers the price target from $58 to $55.
2 months ago zacks.com
Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Lags Revenue Estimates
Janux Therapeutics, Inc. (JANX) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to a loss of $0.55 per share a year ago.
-
2 months ago benzinga.com
Janux Therapeutics Q2 EPS $(0.35) Beats $(0.38) Estimate, Sales $10.267M Miss $16.493M Estimate
Janux Therapeutics (NASDAQ:JANX) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.38) by 7.89 percent. This is a 36.36 percent increase over losses of…
2 months ago businesswire.com
Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial…
-
4 months ago benzinga.com
Truist Securities Assumes Janux Therapeutics at Buy, Lowers Price Target of $26
Truist Securities analyst Supawat Thongthip assumes Janux Therapeutics (NASDAQ:JANX) with a Buy rating and lowers Price Target of $26.
5 months ago zacks.com
Wall Street Analysts Predict a 155.82% Upside in Janux Therapeutics (JANX): Here's What You Should Know
The mean of analysts' price targets for Janux Therapeutics (JANX) points to a 155.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement…
5 months ago zacks.com
Here's Why You Should Add JANX Stock to Your Portfolio Now
Janux Therapeutics advances multiple oncology and immune therapy programs with key clinical updates, new studies and expanded partnerships with BMY and MRK.
-
5 months ago benzinga.com
Piper Sandler Maintains Overweight on Janux Therapeutics, Lowers Price Target to $26
Piper Sandler analyst Kelsey Goodwin maintains Janux Therapeutics (NASDAQ:JANX) with a Overweight and lowers the price target from $30 to $26.
-
5 months ago benzinga.com
Wedbush Maintains Outperform on Janux Therapeutics, Lowers Price Target to $36
Wedbush analyst Robert Driscoll maintains Janux Therapeutics (NASDAQ:JANX) with a Outperform and lowers the price target from $45 to $36.
-
5 months ago benzinga.com
Guggenheim Maintains Buy on Janux Therapeutics, Lowers Price Target to $58
Guggenheim analyst Brad Canino maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and lowers the price target from $68 to $58.
5 months ago zacks.com
Janux Therapeutics, Inc. (JANX) Reports Q1 Loss, Lags Revenue Estimates
Janux Therapeutics, Inc. (JANX) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.5. This compares to a loss of $0.38 per share a year ago.
5 months ago businesswire.com
Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial…
5 months ago zacks.com
How Much Upside is Left in Janux Therapeutics (JANX)? Wall Street Analysts Think 180.44%
The consensus price target hints at an 180.4% upside potential for Janux Therapeutics (JANX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in…
6 months ago seekingalpha.com
Janux Therapeutics: Strong Buy As Pipeline Advances, Stock Trades Below Cash Value
Janux Therapeutics, Inc. is upgraded to Strong Buy, trading below cash value with a robust cash runway and validated technology platforms. Discontinuation of JANX008 demonstrates financial…
-
6 months ago benzinga.com
Jones Trading Maintains Buy on Janux Therapeutics, Lowers Price Target to $28
Jones Trading analyst Boris Peaker maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and lowers the price target from $50 to $28.
6 months ago benzinga.com
Janux Therapeutics Halts Early Stage Cancer Program In 'Prudent' Move
Janux Therapeutics halts JANX008 after Phase 1a review, shifting focus to higher-priority programs despite limited but durable responses.
-
6 months ago benzinga.com
Janux Therapeutics Discontinues JANX008 Cancer Program To Prioritize Higher-Potential Pipeline Opportunities
Janux Therapeutics, Inc. (NASDAQ:JANX) ("Janux"), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that it will discontinue further…
6 months ago businesswire.com
Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (“Janux”), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that it…
-
6 months ago benzinga.com
Barclays Downgrades Janux Therapeutics to Underweight, Lowers Price Target to $14
Barclays analyst Etzer Darout downgrades Janux Therapeutics (NASDAQ:JANX) from Overweight to Underweight and lowers the price target from $29 to $14.
-
6 months ago benzinga.com
Janux Therapeutics Doses First Participant In Phase 1 Clinical Study Of JANX014 To Treat Metastatic Castration-Resistant Prostate Cancer
Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that the first patient has been dosed…
6 months ago businesswire.com
Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that the…
-
6 months ago benzinga.com
UBS Downgrades Janux Therapeutics to Neutral, Lowers Price Target to $15
UBS analyst David Dai downgrades Janux Therapeutics (NASDAQ:JANX) from Buy to Neutral and lowers the price target from $57 to $15.
7 months ago zacks.com
Janux Therapeutics Secures $35M Milestone Payment From BMY Deal
JANX earns $35M milestone payment from Bristol Myers as TRACTr-based cancer candidate advances, signaling progress in its tumor-activated therapy platform.
-
7 months ago benzinga.com
Janux Therapeutics Nominates Development Candidate Under Collaboration, License Agreement With Bristol Myers Squibb
Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced the nomination of a development…
7 months ago businesswire.com
Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced the…
7 months ago defenseworld.net
Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Shares of Janux Therapeutics, Inc. (NASDAQ: JANX - Get Free Report) have been assigned an average rating of "Moderate Buy" from the fourteen ratings firms that are currently covering the stock,…
-
8 months ago benzinga.com
Cantor Fitzgerald Maintains Overweight on Janux Therapeutics, Lowers Price Target to $100
Cantor Fitzgerald analyst Josh Schimmer maintains Janux Therapeutics (NASDAQ:JANX) with a Overweight and lowers the price target from $150 to $100.
-
8 months ago benzinga.com
Guggenheim Maintains Buy on Janux Therapeutics, Lowers Price Target to $68
Guggenheim analyst Brad Canino maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and lowers the price target from $72 to $68.
-
8 months ago benzinga.com
Janux Therapeutics Q4 EPS $(0.51) Beats $(0.64) Estimate
Janux Therapeutics (NASDAQ:JANX) reported quarterly losses of $(0.51) per share which beat the analyst consensus estimate of $(0.64) by 20.19 percent. This is a 41.67 percent decrease over losses of…
8 months ago businesswire.com
Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial…
9 months ago benzinga.com
Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million
Janux Therapeutics signs a global licensing deal with Bristol Myers Squibb worth up to $800 million.
9 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
-
9 months ago benzinga.com
Janux Therapeutics Announces Collaboration And Exclusive Worldwide License Agreement With Bristol Myers Squibb To Develop Undisclosed Tumor-Activated Therapeutics For Solid Tumors
Janux Therapeutics, Inc. (NASDAQ:JANX) ("Janux"), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor…
-
9 months ago benzinga.com
Clear Street Downgrades Janux Therapeutics to Hold, Lowers Price Target to $12
Clear Street analyst Kaveri Pohlman downgrades Janux Therapeutics (NASDAQ:JANX) from Buy to Hold and lowers the price target from $32 to $12.
-
9 months ago benzinga.com
Piper Sandler Maintains Overweight on Janux Therapeutics, Lowers Price Target to $30
Piper Sandler analyst Kelsey Goodwin maintains Janux Therapeutics (NASDAQ:JANX) with a Overweight and lowers the price target from $42 to $30.
-
10 months ago benzinga.com
Janux Therapeutics Provides Phase 1 Update on EGFR-Targeted JANX008; The Program Has Initiated Expansion Cohorts To Enable Further Evaluation And Support Continued Dose Optimization Across Selected Solid Tumor Settings
Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies based on its proprietary Tumor Activated T Cell Engager…
-
10 months ago benzinga.com
Barclays Maintains Overweight on Janux Therapeutics, Lowers Price Target to $29
Barclays analyst Etzer Darout maintains Janux Therapeutics (NASDAQ:JANX) with a Overweight and lowers the price target from $48 to $29.
11 months ago benzinga.com
Gold Down Over 1%; Signet Shares Fall After Q3 Results
Gold Down Over 1%; Signet Shares Fall After Q3 Results
-
11 months ago benzinga.com
Stifel Maintains Buy on Janux Therapeutics, Lowers Price Target to $38
Stifel analyst Bradley Canino maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and lowers the price target from $46 to $38.
11 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
11 months ago benzinga.com
Janux Therapeutics Stock Hits 52-Week Low After Trial Update
JANX stock hit 52-week low after releasing Phase 1 data for JANX007 in mCRPC. Encouraging efficacy and safety profile observed in trials.